Merck & Co., Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q4 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Merck & Co., Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q4 2010 to Q3 2024.
  • Merck & Co., Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending September 30, 2024 was $11.4B, a 9.5% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $11.4B +$987M +9.5% Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $11.6B +$612M +5.55% Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $11.4B +$951M +9.13% Mar 31, 2024 10-Q 2024-05-03
Q4 2023 $10.3B +$899M +9.51% Dec 31, 2023 10-Q 2024-11-06
Q3 2023 $10.4B +$912M +9.62% Sep 30, 2023 10-Q 2023-11-03
Q2 2023 $11B +$1.39B +14.4% Jun 30, 2023 10-Q 2023-08-07
Q1 2023 $10.4B +$587M +5.97% Mar 31, 2023 10-Q 2023-05-05
Q4 2022 $9.45B +$220M +2.38% Dec 31, 2022 10-K 2024-02-26
Q3 2022 $9.48B +$911M +10.6% Sep 30, 2022 10-Q 2022-11-03
Q2 2022 $9.64B +$1.8B +23% Jun 30, 2022 10-Q 2022-08-05
Q1 2022 $9.83B +$1.59B +19.3% Mar 31, 2022 10-Q 2022-05-05
Q4 2021 $9.23B +$2.43B +35.7% Dec 31, 2021 10-K 2023-02-24
Q3 2021 $8.57B +$149M +1.77% Sep 30, 2021 10-Q 2021-11-05
Q2 2021 $7.84B +$266M +3.51% Jun 30, 2021 10-Q 2021-08-09
Q1 2021 $8.24B +$53M +0.65% Mar 31, 2021 10-Q 2021-05-05
Q4 2020 $6.8B +$25M +0.37% Dec 31, 2020 10-K 2022-02-25
Q3 2020 $8.42B -$20M -0.24% Sep 30, 2020 10-Q 2020-11-05
Q2 2020 $7.58B -$387M -4.86% Jun 30, 2020 10-Q 2020-08-05
Q1 2020 $8.18B +$574M +7.55% Mar 31, 2020 10-Q 2020-05-06
Q4 2019 $6.78B -$293M -4.14% Dec 31, 2019 10-K 2021-02-25
Q3 2019 $8.44B +$1.07B +14.5% Sep 30, 2019 10-Q 2019-11-05
Q2 2019 $7.96B +$677M +9.29% Jun 30, 2019 10-Q 2019-08-06
Q1 2019 $7.61B +$363M +5.01% Mar 31, 2019 10-Q 2019-05-08
Q4 2018 $7.07B +$198M +2.88% Dec 31, 2018 10-K 2020-02-26
Q3 2018 $7.37B -$297M -3.87% Sep 30, 2018 10-Q 2018-11-06
Q2 2018 $7.29B -$152M -2.04% Jun 30, 2018 10-Q 2018-08-07
Q1 2018 $7.25B +$179M +2.53% Mar 31, 2018 10-Q 2018-05-08
Q4 2017 $6.87B -$145M -2.07% Dec 31, 2017 10-K 2019-02-27
Q3 2017 $7.67B +$307M +4.17% Sep 30, 2017 10-Q 2017-11-07
Q2 2017 $7.44B +$523M +7.56% Jun 30, 2017 10-Q 2017-08-08
Q1 2017 $7.07B +$216M +3.15% Mar 31, 2017 10-Q 2017-05-09
Q4 2016 $7.02B +$534M +8.24% Dec 31, 2016 10-K 2018-02-27
Q3 2016 $7.36B +$950M +14.8% Sep 30, 2016 10-Q 2016-11-07
Q2 2016 $6.92B +$406M +6.24% Jun 30, 2016 10-Q 2016-08-08
Q1 2016 $6.85B +$180M +2.7% Mar 31, 2016 10-Q 2016-05-09
Q4 2015 $6.48B -$142M -2.14% Dec 31, 2015 10-K 2017-02-28
Q3 2015 $6.41B -$101M -1.55% Sep 30, 2015 10-Q 2015-11-05
Q2 2015 $6.51B -$512M -7.29% Jun 30, 2015 10-Q 2015-08-06
Q1 2015 $6.67B -$518M -7.21% Mar 31, 2015 10-Q 2015-05-07
Q4 2014 $6.63B -$558M -7.77% Dec 31, 2014 10-K 2016-02-26
Q3 2014 $6.52B -$1.06B -14% Sep 30, 2014 10-Q 2014-11-10
Q2 2014 $7.02B -$757M -9.73% Jun 30, 2014 10-Q 2014-08-07
Q1 2014 $7.19B -$777M -9.76% Mar 31, 2014 10-Q 2014-05-08
Q4 2013 $7.18B -$488M -6.36% Dec 31, 2013 10-K 2015-02-27
Q3 2013 $7.58B -$374M -4.7% Sep 30, 2013 10-Q 2013-11-07
Q2 2013 $7.78B -$373M -4.58% Jun 30, 2013 10-Q 2013-08-07
Q1 2013 $7.97B -$761M -8.72% Mar 31, 2013 10-Q 2013-05-09
Q4 2012 $7.67B -$589M -7.13% Dec 31, 2012 10-K 2014-02-27
Q3 2012 $7.95B -$184M -2.26% Sep 30, 2012 10-Q 2012-11-09
Q2 2012 $8.15B -$323M -3.81% Jun 30, 2012 10-Q 2012-08-07
Q1 2012 $8.73B Mar 31, 2012 10-Q 2012-05-08
Q4 2011 $8.26B +$917M +12.5% Dec 31, 2011 10-K 2013-02-28
Q3 2011 $8.14B Sep 30, 2011 10-Q 2011-11-08
Q2 2011 $8.48B Jun 30, 2011 10-Q 2011-08-08
Q4 2010 $7.34B Dec 31, 2010 10-K 2012-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.